CO43 Projecting Cardiovascular Benefits Associated With Tirzepatide's Effects on Cardiovascular Risk Factors in Patients With Type 2 Diabetes in France: A Simulation Study

Tirzepatide is a GIP/GLP-1 receptor agonist approved for the treatment of type 2 diabetes (T2D) that is associated with superior reductions in glycated hemoglobin and body weight versus a range of existing therapies. The present analysis aimed to model the benefits on cardiovascular (CV) outcomes associated with tirzepatide from demonstrated improvements in CV risk factors (RF) versus no change in RF, with a focus on major adverse cardiovascular events (MACE) as the primary outcome.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research